186 related articles for article (PubMed ID: 32492742)
41. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Chen YW; Rini BI
Curr Oncol Rep; 2022 Jun; 24(6):695-702. PubMed ID: 35247142
[TBL] [Abstract][Full Text] [Related]
42. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
43. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
[TBL] [Abstract][Full Text] [Related]
44. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
45. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
46. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
[TBL] [Abstract][Full Text] [Related]
48. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
Adrianzen Herrera DA; Fleisig SB; Gartrell BA
Invest New Drugs; 2017 Oct; 35(5):665-668. PubMed ID: 28466375
[TBL] [Abstract][Full Text] [Related]
49. Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma.
Ishihara H; Nemoto Y; Tachibana H; Ikeda T; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Clin Genitourin Cancer; 2024 Apr; 22(2):549-557.e5. PubMed ID: 38281878
[TBL] [Abstract][Full Text] [Related]
50. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
51. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Joseph RW; Chatta G; Vaishampayan U
Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
[TBL] [Abstract][Full Text] [Related]
53. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
54. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
55. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
56. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
57. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
58. Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy.
Sazuka T; Nihei N; Nakamura K; Sakamoto S; Fukasawa S; Komaru A; Ueda T; Igarashi T; Ichikawa T
Korean J Urol; 2015 Mar; 56(3):205-11. PubMed ID: 25763124
[TBL] [Abstract][Full Text] [Related]
59. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers.
Starzer AM; Wolff L; Popov P; Kiesewetter B; Preusser M; Berghoff AS
Cancer Treat Rev; 2024 Apr; 125():102718. PubMed ID: 38521009
[TBL] [Abstract][Full Text] [Related]
60. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.
Grimm MO; Leucht K; Grünwald V; Foller S
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32092974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
